A Phase I/IIa study to evaluate the safety and efficacy of CCS1477, a first in clinic inhibitor of p300/CBP, as monotherapy in patients with selected molecular alterations

Targeting p300/CBP axis in lethal prostate cancer

Unique and Shared Epigenetic Programs of the CREBBP and EP300 Acetyltransferases in Germinal Center B Cells Reveal Targetable Dependencies in Lymphoma

Inobrodib: A novel small molecule inhibitor of p300/CBP for the treatment of acute myeloid leukaemia and multiple myeloma

An open-label Phase I/IIa study to evaluate the safety and efficacy of Inobrodib, a first in clinic inhibitor of the p300/CBP bromodomains, as monotherapy in patients with advanced haematological malignancies

An open-label Phase I/IIa study to evaluate the safety and efficacy of Inobrodib as monotherapy and in combination in patients with advanced solid/metastatic tumours.

Inobrodib, a potent and selective p300/CBP bromodomain inhibitor, is targeted and differentiated from BET inhibitors in prostate cancer cell lines in vitro.

p300/CBP inhibitor CCS1477 targets 22Rv1 prostate tumour AR and c-Myc gene expression in vivo.

A first-in-class p300/CBP bromodomain inhibitor for the treatment of prostate cancer and hematologic malignancies.

Novel small molecule inhibitor of p300/CBP down-regulates androgen receptor (AR) and c-Myc for the treatment of prostate cancer and beyond

Therapeutic targeting of the p300/CBP bromodomain for the treatment of castration resistant prostate cancer (CRPC)

Targeting the bromodomain of p300/CBP for the treatment of castrate resistant prostate cancer